BioTech 365
OCTOBER 19, 2021
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology’s Targeted Radionuclide Therapy candidate FAP-2286 BOULDER, … Continue reading (..)
Outsourcing Pharma
AUGUST 15, 2022
Signant Health has partnered with the software company o connect its platforms for the management of clinical supply chain inventory, labels, and content.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 14, 2020
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
The Pharma Data
SEPTEMBER 15, 2020
Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.
The Pharma Data
JANUARY 10, 2021
About MorphoSys MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc.,
The Pharma Data
JANUARY 24, 2021
Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Research and development efforts will be led by Dr. Paul Van Slyke. . – January 25, 2021) – PharmaDrug Inc. About PharmaDrug Inc.
The Pharma Data
OCTOBER 27, 2020
Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.
Expert insights. Personalized for you.
52 
Let's personalize your content